๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Adjuvant Therapy
Clinical trial register · China

Adjuvant Therapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Chengdu 3 Nanjing 3 Nanning 2 Beijing 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Chengdu3 Nanjing3 Nanning2 Beijing2
All 8 locations
Target enrolment
to

Adjuvant Therapy trials in China

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
NCT07303283Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
Kai Hu
Phase 2
140
Nanning
2026-09-01
Not yet open
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
NCT07686185Non-Small Cell Lung Cancer, Adjuvant Therapy
First Affiliated Hospital of Guangxi Medical University
Observational
500
Nanning
2026-09-01
Recruiting
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
NCT07622836TNBC, Adjuvant Therapy, Lymph Node Positive
The First Affiliated Hospital with Nanjing Medical University
Not applicable
59
Nanjing
2026-06-05
Not yet open
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
NCT07466901Cervical Cancer, Radical Surgery, Adjuvant Therapy
Jin LI
Not applicable
30
Shanghai
2026-04-01
Recruiting
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
NCT07479667Solid Cancers, Adjuvant Therapy
Shanghai Cell Therapy Group Co.,Ltd
Phase 1
8
Shanghai
2026-02-05
Recruiting
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT07019363Breast Cancer, Adjuvant Therapy
Fudan University
Phase 3
1,903
Shanghai
2025-06-15
Recruiting
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
NCT06950814Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
West China Hospital
Observational
50
Chengdu
2025-04-05
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Active, closed
MRD in PAAD Adjuvant Therapy
NCT06867146The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy
Peking Union Medical College Hospital
Not applicable
60
Beijing
2024-10-15
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
NCT06361316Pancreatic Cancer, Adjuvant Therapy
Kuirong Jiang
Not applicable
53
Nanjing
2024-04-08
Recruiting
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
NCT06344156Pancreatic Cancer, Adjuvant Therapy
Sichuan University
Phase 1
43
Chengdu
2024-04-01
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
Guo Xufeng
Phase 2
73
Shanghai
2023-09-07
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
Fudan University
Phase 2
94
Shanghai
2022-08-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/adjuvant-therapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies listing the condition Adjuvant Therapy.

How many Adjuvant Therapy trials are recruiting in China?

11 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Adjuvant Therapy), 16 studies
PhaseStudiesRecruitingShare
Not applicable5331.3%
Phase 25331.3%
Observational2112.5%
Phase 12212.5%
Phase 32212.5%

Most active sponsors

Lead sponsors with the most studies (Adjuvant Therapy)
Lead sponsorStudiesRecruiting
Fudan University21
Sichuan University22
Betta Pharmaceuticals Co., Ltd.11
First Affiliated Hospital of Guangxi Medical University10
Fujian Medical University Union Hospital11
Guo Xufeng11
Jin LI10
Kai Hu10
Kuirong Jiang11
Peking Union Medical College Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.